Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2010 Feb;45(2):192-6.
doi: 10.1002/ppul.21139.

Acute pulmonary toxicity following intralesional administration of bleomycin for a lymphovenous malformation

Affiliations
Case Reports

Acute pulmonary toxicity following intralesional administration of bleomycin for a lymphovenous malformation

Khalid Atwa et al. Pediatr Pulmonol. 2010 Feb.

Abstract

Objective: To describe the clinical course and treatment of an infant with acute pulmonary toxicity following intralesional administration of bleomycin for a lymphovenous malformation.

Design: Case report.

Setting: A tertiary care University-affiliated hospital.

Patient, intervention, and results: An 8-month-old girl developed acute respiratory distress with profound hypoxemia complicated by pneumothorax and pneumomediastinum 1 day following intralesional administration of bleomycin. She was treated with bilateral chest tube insertion, systemic corticosteroids, pentoxifylline, and supportive care. At the most recent follow-up 5 months after the onset of the respiratory event, the patient is active, walks, and talks without any evidence of pulmonary diseases clinically. This is the youngest infant reported, to date, with acute bleomycin pulmonary toxicity following intralesional administration of bleomycin resulting in acute respiratory insufficiency followed by complete recovery.

Conclusions: This case illustrates the importance of early recognition and aggressive treatment of acute bleomycin toxicity resulting from intralesional administration of this medication for lymphovenous malformations.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources